Systemic Lupus Erythematosus

dc.contributor.author	Breke, Ali Mohamed Ali
dc.date.accessioned	2019-02-02T11:19:22Z
dc.date.available	2019-02-02T11:19:22Z
dc.date.issued	2018-05-05
dc.identifier.uri	http://repository.limu.edu.ly/handle/123456789/412
dc.description	Systemic lupus erythematosus (SLE) is autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many part of the body. The SLE is chronic inflammatory disease that has protean manifestations and follows a relapsing and remitting course. More than 90% of cases of SLE occur in women, frequently starting at childbearing age. Common symptoms include painful and swollen lymph nodes, feeling tired, and a red rash which is commonly in the face. SLE can occur in up to 20% of patients 50 years of age or older. SLE affects almost every system in the body, with varying degrees of severity. Recent advances in our understanding of the genetic, molecular and cellular basis of autoimmune diseases and especially SLE have led to the application of novel and targeted treatments. This article reviews the general approach to the therapy of SLE, focusing on current approved therapies	en_US
dc.language.iso	en	en_US
dc.publisher	faculty of Basic Medical Science - Libyan International Medical University	en_US
dc.rights	Attribution 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by/3.0/us/	*
dc.title	Systemic Lupus Erythematosus	en_US
dc.type	Other	en_US

Except where otherwise noted, this item's license is described as Attribution 3.0 United States